Document is current
Any future updates will be listed below
-
Authors
Vasconcelos, Huber M. Jr. https://orcid.org/0000-0001-5619-3188
Lujan, Brandon J.
Pennesi, Mark E.
Yang, Paul
Lauer, Andreas K.
-
Funding
Funding for this research was provided by:
GOAP
National Institutes of Health (K08EY026650)
Foundation Fighting Blindness (NMT-0714-648)
Unrestricted Grant from Research to Prevent Blindness
- License Information
-
More Information
Article History
Received: 20 November 2019
Accepted: 24 March 2020
First Online: 1 May 2020
Ethics approval and consent to participate
: The study and related clinical trials protocols were conducted according to the Declaration of Helsinki, relevant national and local requirements, and was approved by the Ethical Review Board for Human Research of the Oregon Health & Science University.
: Not applicable.
: HMV—No competing interests. BJL—Translational Imaging Innovations, Inc: advisor/stock; University of California, Berkeley: patent/IP. MEP—Editas/Allergan: consultant; ProQR Therapeutics: consultant; Nacuity Pharmaceuticals: consultant; Astellas Pharmaceuticals: consultant; Gensight: consultant; Horama: consultant; Sparks Therapeutics: consultant; Wavemetrics: consultant; Eyevensys: consultant; Nayan: consultant; AGTC: consultant/clinical trial support; Sanofi: consultant/clinical trial support; Foundation Fighting Blindness: consultant; Nightstar/Biogen: consultant/clinical trial support. PY—Sparks Therapeutics: clinical trial support; AGTC: clinical trial support; Sanofi: clinical trial support; Foundation Fighting Blindness: clinical trial support; Nightstar/Biogen: clinical trial support; Acucela: clinical trial support. AKL – Editas/Allergan: clinical trial support; Genentech: clinical trial support; IVERIC bio: clinical trial support; Nightstar/Biogen: clinical trial support; Sanofi: clinical trial support.
